ES2100148T3 - Aplicaciones terapeuticas de los agonistas beta-adrenergicos. - Google Patents

Aplicaciones terapeuticas de los agonistas beta-adrenergicos.

Info

Publication number
ES2100148T3
ES2100148T3 ES88308402T ES88308402T ES2100148T3 ES 2100148 T3 ES2100148 T3 ES 2100148T3 ES 88308402 T ES88308402 T ES 88308402T ES 88308402 T ES88308402 T ES 88308402T ES 2100148 T3 ES2100148 T3 ES 2100148T3
Authority
ES
Spain
Prior art keywords
beta
effects
adrenergic
adrenergic agonists
reversing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88308402T
Other languages
English (en)
Inventor
Charlotte Anne Maltin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rowett Research Institute
Original Assignee
Rowett Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878721602A external-priority patent/GB8721602D0/en
Priority claimed from GB888803619A external-priority patent/GB8803619D0/en
Application filed by Rowett Research Institute filed Critical Rowett Research Institute
Application granted granted Critical
Publication of ES2100148T3 publication Critical patent/ES2100148T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS EMPLEOS TERAPEUTICOS DE AGONISTAS BETA - ADRENERGICOS EN HOMBRES Y ANIMALES. LAS APLICACIONES INCLUYEN AUMENTAR EL CRECIMIENTO MUSCULAR Y REDUCIR LA ABSORCION DE GRASA DE LA INGESTA, RETARDAR O INVERTIR LA ATROFIA DE MUSCULOS DESNERVADOS, ALIVIAR O INVERTIR LOS EFECTOS DE VARIAS ENFERMEDADES (INCLUYENDO EL CANCER), MODIFICACION DEL CRECIMIENTO FETAL Y NEONATAL Y MODIFICACIONES GENETICAS DEL FETO EN DESARROLLO. ES AGONISTA BETA - ADRENERGICO PREFERIDO ES EL CLENBUTEROL. SORPRENDENTEMENTE EL AGONISTA BETA - ADRENERGICO SE PUEDE MEZCLAR CON UN ANTAGONISTA BETA - ADRENERGICO PARA OBVIAR O MITIGAR LOS EFECTOS SECUNDARIOS INDESEADOS, SIN INHIBIR EXCESIVAMENTE LOS EFECTOS NUEVOS DESEABLES.
ES88308402T 1987-09-15 1988-09-12 Aplicaciones terapeuticas de los agonistas beta-adrenergicos. Expired - Lifetime ES2100148T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878721602A GB8721602D0 (en) 1987-09-15 1987-09-15 Therapeutic applications of beta-adrenergic agonists
GB888803619A GB8803619D0 (en) 1988-02-17 1988-02-17 Therapeutic applications of beta-adrenergic agonists

Publications (1)

Publication Number Publication Date
ES2100148T3 true ES2100148T3 (es) 1997-06-16

Family

ID=26292734

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88308402T Expired - Lifetime ES2100148T3 (es) 1987-09-15 1988-09-12 Aplicaciones terapeuticas de los agonistas beta-adrenergicos.

Country Status (4)

Country Link
EP (2) EP0308157B1 (es)
AT (1) ATE149089T1 (es)
DE (1) DE3855801T2 (es)
ES (1) ES2100148T3 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU203040B (en) * 1988-07-05 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing weight-increasing composition containing 1-(3,5-dihydroxy-phenyl)-2-(terc-butyl-amino)-ethanol
US5281623A (en) * 1990-08-27 1994-01-25 Eli Lilly And Company Method for treating inflammation
EP0488435A1 (en) * 1990-11-26 1992-06-03 Duphar International Research B.V Method of increasing the muscle/fat ratio in agricultural domestic animals
US6524532B1 (en) 1995-06-20 2003-02-25 The Regents Of The University Of California Microfabricated sleeve devices for chemical reactions
US6015837A (en) * 1996-08-29 2000-01-18 New York Medical College Method for treating scoliosis with β2-adrenoceptor agonists
CA2455248A1 (en) * 2004-01-29 2005-07-29 Alexander Zolotoy Oral administration of r-albuterol against obesity
US8080528B2 (en) 2005-12-22 2011-12-20 The Releef Initiative Compositions and methods for treatment of cachexia
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
EA018918B1 (ru) 2007-04-24 2013-11-29 Экейше Фарма Лимитед КОМБИНАЦИЯ, СОДЕРЖАЩАЯ β-АГОНИСТ И ПРОГЕСТИН, И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ АТРОФИИ МЫШЕЧНОЙ ТКАНИ
PL220308B1 (pl) 2011-06-03 2015-10-30 Kobel Buys Krystyna Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60530A (en) * 1979-08-16 1984-10-31 American Cyanamid Co Animal feed compositions useful as growth promotors and for reduction of fat in animals,comprising phenylethanolamine derivatives and certain such novel compounds
DE3481754D1 (de) * 1983-01-31 1990-05-03 Lilly Co Eli Wachstumsfoerderung von tieren mit phenaethanolaminen.
GB8806471D0 (en) * 1988-03-18 1988-04-20 Tisdale M J Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours

Also Published As

Publication number Publication date
EP0308157A3 (en) 1992-01-15
EP0662324A1 (en) 1995-07-12
EP0308157A2 (en) 1989-03-22
ATE149089T1 (de) 1997-03-15
DE3855801D1 (de) 1997-04-03
DE3855801T2 (de) 1997-07-03
EP0308157B1 (en) 1997-02-26

Similar Documents

Publication Publication Date Title
ES2100148T3 (es) Aplicaciones terapeuticas de los agonistas beta-adrenergicos.
ATA242288A (de) Dosierungsform für die behandlung kardiovaskulärer erkrankungen
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
EP0401903A3 (en) The use of vanilloids for the treatment of respiratory diseases or disorders
IL68350A (en) N-glycosylated carboxamide derivatives,their preparation and their use for the treatment of animals
ZA898605B (en) Compositions for topical treatment of skin diseases
EP0417003A3 (en) Use of antiprogestomimetics for stimulating ovulation
IL83775A0 (en) Fumaramide derivatives and pharmaceutical compositions containing them for treating skin diseases
DE69034076D1 (de) Verwendung von Human-Beta-Interferon zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von chronischer Myeloidleukämie
DE3889974D1 (de) Pyrazol-Derivate und diese enthaltende Behandlungsmittel für cerebrovaskulare Krankheiten.
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
FR2600256B1 (fr) Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus
DE3273389D1 (en) Derivatives of pentacyclo undecanes, processes for preparing these compounds, and pharmeceutical compositions thereof
DE3775278D1 (de) Topische methotrexatzubereitung zur behandlung hyperproliferativer epithelerkrankungen.
FR2399406A1 (fr) Derives de perhydronaphtalenepentol et leur utilisation therapeutique
FR2419291A1 (fr) 2,3-dihydroimidazo(1,2-c)pyrimidines substituees et leur utilisation therapeutique
KR890017363A (ko) 스트로빌루린 유도체, 이들의 제법 및 용도
DE3374066D1 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor
DE69011272D1 (de) 3-Substituierte-2-Oxindolderivate als Interleukin-Biosynthesehemmer.
ATE197764T1 (de) Zusammensetzung zur behandlung des insulinmangels bei säugetieren, die amylin und insulin enthält.
FR2401910A1 (fr) Derives de thio-uree et leur utilisation therapeutique
DE69118847D1 (de) Verwendung von Heptastigmin zur Behandlung der zerebralen Ictus
BE885851A (fr) Composition therapeutique pour le traitement de la dustrophie musculaire, de la myopathie et de la myotonie
IL86731A0 (en) Pharmaceutical compositions containing estradien-3-one derivatives and androst-2-ene-2-carbonitrile derivatives
SU1797195A1 (ru) Способ профилактики радиационных поражений

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 308157

Country of ref document: ES